Biological evaluation of the effect of sugammadex on hemostasis and bleeding

Korean Journal of Anesthesiology

Volumn 68, Issue 1, 2015, Pages 17-21

  Raft, Julien ^a   Guerci, Philippe ^a,c   Harter, Valentin ^b   Fuchs Buder, Thomas ^c   Meistelman, Claude ^a,c  

^a Departments of Anesthesiology   (Bangladesh)

^b Epidemiology Unit   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Activated partial thromboplastin time; Hemostasis; Prothrombin time; Sugammadex

Indexed keywords

ENOXAPARIN; NEOSTIGMINE; SUGAMMADEX;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CELL COUNT; BLOOD CLOTTING TEST; BLOOD SAMPLING; BODY MASS; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROMUSCULAR BLOCKING; OBSERVATIONAL STUDY; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDY; PROTHROMBIN TIME; SCORING SYSTEM;

EID: 84923167643     PISSN: 20056419     EISSN: 20057563     Source Type: Journal    
DOI: 10.4097/kjae.2015.68.1.17     Document Type: Article

References (10)

1. Plaud B, Debaene B, Donati F, Marty J. Residual paralysis after emergence from anesthesia. Anesthesiology 2010; 112: 1013-22.
2. Naguib M. Sugammadex: Another milestone in clinical neuromuscular pharmacology. Anesth Analg 2007; 104: 575-81.
3. Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, A novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103: 695-703.
4. Adam JM, Bennett DJ, Bom A, Clark JK, Feilden H, Hutchinson EJ, et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: Synthesis and structure-activity relationships. J Med Chem 2002; 45: 1806-16.
5. Raft J, Betala Belinga JF, Jurkolow G, Desandes E, Longrois D, Meistelman C. Clinical evaluation of post-surgical bleeding after a sugammadex injection. Ann Fr Anesth Reanim 2011; 30: 714-7.
6. Reed RL, Johnston TD, Chen Y, Fischer RP. Hypertonic saline alters plasma clotting times and platelet aggregation. J Trauma 1991; 31: 8-14.
7. Michelson AD, McGregor H, Barnard MR, Kestin AS, Rohrer MJ, Valeri CR. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost 1994; 71: 633-40.
8. Reed RL, Johnson TD, Hudson JD, Fischer RP. The disparity between hypothermic coagulopathy and clotting studies. J Trauma 1992; 33: 465-70.
9. Felfernig M, Blaicher A, Kettner SC, Felfernig D, Acimovic S, Kozek-Langenecker SA. Effects of temperature on partial thromboplastin time in heparinized plasma in vitro. Eur J Anaesthesiol 2001; 18: 467-70.
10. De Kam PJ, Kruithof AC, Van Lierop MJ, Moerland M, Dennie J, Troyer MD, et al. Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects. Int J Clin Pharmacol Ther 2014; 52: 631-41.